Kocis Paul T, Mallinson Daniel J, Servinsky Timothy J
Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA.
School of Public Affairs, Penn State University, Harrisburg, PA, USA.
Med Cannabis Cannabinoids. 2024 Jul 17;7(1):119-124. doi: 10.1159/000539956. eCollection 2024 Jan-Dec.
With the continued societal and policy interest in cannabinoids, the Penn State Harrisburg Center for Survey Research (CSR) conducted a web survey (Cannabinoid Lion Poll) for adult-aged Pennsylvanians between March 6 and April 2, 2023.
The Lion Poll omnibus survey asked questions of adult-aged Pennsylvanians to assess awareness of cannabidiol (CBD) and products containing tetrahydrocannabinol (THC), including marijuana, the likelihood of reporting cannabinoid use to health care providers (HCPs), and perceptions regarding safety.
Of these 1,045 respondents, 51.2% were female; 83.0% were white, non-Hispanic; and 48.6% and 27.5% were within the 35-64-year and 18-34-year age ranges, respectively. Of the respondents, 52.1% and 53.9% told their HCPs they took CBD or products containing THC, respectively. Alcohol was perceived by the large proportion of respondents as unsafe (47.3%), followed by products containing THC (25.2%), anxiety/depression medications (21.7%), CBD (16.1%), and over-the-counter (OTC) pain medications (8.1%). Most combinations were perceived to be unsafe when asked to consider the safety of taking them with other prescription medications. Again, alcohol was perceived to be unsafe by the largest proportion (77.4%), followed by anxiety/depression medications (43.2%), products containing THC (42.6%), CBD (33.4%), and then OTC pain medications (24.8%).
Adult-aged Pennsylvanians perceive CBD and THC containing products as safer than alcohol. There is considerable underreporting of cannabinoid use to HCPs, and therefore significant implications for patient safety. It remains vital that HCPs have open communications with their patients about cannabinoid use.
随着社会和政策对大麻素持续关注，宾夕法尼亚州立大学哈里斯堡分校调查研究中心（CSR）于2023年3月6日至4月2日对宾夕法尼亚州成年居民开展了一项网络调查（大麻素狮子民意调查）。
狮子民意综合调查向宾夕法尼亚州成年居民提问，以评估他们对大麻二酚（CBD）以及含四氢大麻酚（THC）产品（包括大麻）的认知、向医疗服务提供者（HCP）报告使用大麻素情况的可能性以及对安全性的看法。
在这1045名受访者中，51.2%为女性；83.0%为非西班牙裔白人；分别有48.6%和27.5%的受访者年龄在35 - 64岁和18 - 34岁之间。在受访者中，分别有52.1%和53.9%的人告知其医疗服务提供者他们使用了CBD或含THC的产品。大部分受访者认为酒精不安全（47.3%），其次是含THC的产品（25.2%）、抗焦虑/抑郁药物（21.7%）、CBD（16.1%）和非处方（OTC）止痛药物（8.1%）。当被问及与其他处方药同时服用的安全性时，大多数组合被认为不安全。同样，大部分人认为酒精不安全（77.4%），其次是抗焦虑/抑郁药物（43.2%）、含THC的产品（42.6%）、CBD（33.4%），然后是非处方止痛药物（24.8%）。
宾夕法尼亚州成年居民认为含CBD和THC的产品比酒精更安全。向医疗服务提供者报告使用大麻素的情况严重不足，因此对患者安全有重大影响。医疗服务提供者与患者就大麻素的使用进行开放沟通仍然至关重要。
